Trends in the prevalence of thrombocytopenia among individuals iInfected with hepatitis C Virus in the United States, 1999-2008

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Kauf, Teresa L ^a   Nelson, David R ^b   Schelfhout, Jonathan ^a   Delaney, Joseph Ac ^a   Wang, Peter Feng ^c  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Hepatitis C; NHANES; Platelets; Thrombocytopenia

Indexed keywords

HEPATITIS C VIRUS;

ADULT; AGED; ARTICLE; FEMALE; HEPATITIS C; HUMAN; MALE; MIDDLE AGED; NUTRITION; PREVALENCE; REGRESSION ANALYSIS; STATISTICS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TIME; UNITED STATES;

ADULT; AGED; FEMALE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; NUTRITION SURVEYS; PLATELET COUNT; PREVALENCE; REGRESSION ANALYSIS; THROMBOCYTOPENIA; TIME FACTORS; UNITED STATES;

EID: 84857969147     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-142     Document Type: Article

References (20)

1. Diagnosis, management, and treatment of hepatitis C: an update. Ghany MG, Strader DB, Thomas DL, et al. Hepatology 2009 49 1335 1374 10.1002/hep.22759 19330875
2. Diagnosis, management, and treatment of hepatitis C. Strader DB, Wright T, Thomas DL, et al. Hepatology 2004 39 1147 1171 10.1002/hep.20119 15057920 (Pubitemid 38428955)
3. Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: Implications from a survey of a community with hyperendemic HCV infection. Wang CS, Yao WJ, Wang ST, et al. Clin Infect Dis 2004 39 790 796 10.1086/423384 15472809 (Pubitemid 39244291)
4. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office. Yee HS, Currie SL, Darling JM, et al. Am J Gastroenterol 2006 101 2360 2378 10.1111/j.1572-0241.2006.00754.x 17032203 (Pubitemid 44477566)
5. Thrombocytopenia associated with chronic liver disease. Afdhal N, McHutchison J, Brown R, et al. J Hepatol 2008 48 1000 1007 10.1016/j.jhep.2008. 03.009 18433919
6. Prevalence of thrombocytopenia among patients with chronic hepatitis C: A systematic review. Louie KS, Micallef JM, Pimenta JM, et al. J Viral Hepat 2011 18 1 7 21824223
7. Pegasys (peginterferon alfa-2a) product information. Hoffman-La Roche Inc, http://www.gene.com/gene/products/information/pegasys/pdf/pi.pdf
8. PegIntron (Peginterferon alfa-2b) product information. Schering Corporation, http://www.spfiles.com/pipeg-intron.pdf
9. Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Davis GL, Alter MJ, El-Serag H, et al. Gastroenterology 2010 138 513 521 10.1053/j.gastro.2009.09.067 19861128
10. Projecting future complications of chronic hepatitis C in the United States. Davis GL, Albright JE, Cook SF, Liver Transpl 2003 9 331 338 10.1053/jlts.2003.50073 12682882 (Pubitemid 36443043)
11. The healthcare burden imposed by liver disease in aging Baby Boomers. Davis GL, Roberts WL, Curr Gastroenterol Rep 2010 12 1 6 10.1007/s11894-009- 0087-2 20425478
12. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Wong JB, McQuillan GM, McHutchison JG, et al. Am J Public Health 2000 90 1562 1569 11029989
13. Peripheral blood count abnormalities among patients with hepatitis C in the United States. Streiff MB, Mehta S, Thomas DL, Hepatology 2002 35 947 952 10.1053/jhep.2002.32486 11915043 (Pubitemid 34258391)
14. Trends in health care resource use for hepatitis C virus infection in the United States. Grant WC, Jhaveri RR, McHutchison JG, et al. Hepatology 2005 42 1406 1413 10.1002/hep.20941 16317670 (Pubitemid 43260044)
15. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Jacobson IM, Davis GL, El-Serag H, et al. Clin Gastroenterol Hepatol 2010 8 924 933 10.1016/j.cgh.2010.06.032 20713178
16. Thrombocytopenia in chronic liver disease. Poordad F, Aliment Pharmacol Ther 2007 26 Suppl 1 5 11 17958514
17. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. McHutchison JG, Dusheiko G, Shiffman ML, N Engl J Med 2007 357 2227 2236 10.1056/NEJMoa073255 18046027 (Pubitemid 350190753)
18. New hepatitis C therapies in clinical development. Vermehren J, Sarrazin C, Eur J Med Res 2011 16 303 314 10.1186/2047-783X-16-7-303 21813371
19. A pharmacoeconomic analysis of thrombocytopenia in chronic liver disease. Brown RS Jr, Aliment Pharmacol Ther 2007 26 Suppl 1 41 48 17958518 (Pubitemid 47631864)
20. National Health and Nutrition Examination Survey. Centers for Disease Control and Prevention, http://www.cdc.gov/nchs/nhanes.htm